Cystic Fibrosis - Pipeline Review, H2 2016

Date: September 28, 2016
Pages: 389
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C278BF4B5BEEN
Leaflet:

Download PDF Leaflet

Cystic Fibrosis - Pipeline Review, H2 2016
Cystic Fibrosis - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Cystic Fibrosis - Pipeline Review, H2 2016’, provides an overview of the Cystic Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cystic Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Cystic Fibrosis
  • The report reviews pipeline therapeutics for Cystic Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Cystic Fibrosis therapeutics and enlists all their major and minor projects
  • The report assesses Cystic Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Cystic Fibrosis
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Cystic Fibrosis Overview
Therapeutics Development
Cystic Fibrosis - Therapeutics under Development by Companies
Cystic Fibrosis - Therapeutics under Investigation by Universities/Institutes
Cystic Fibrosis - Pipeline Products Glance
Cystic Fibrosis - Products under Development by Companies
Cystic Fibrosis - Products under Investigation by Universities/Institutes
Cystic Fibrosis - Companies Involved in Therapeutics Development
Cystic Fibrosis - Therapeutics Assessment
Drug Profiles
Cystic Fibrosis - Dormant Projects
Cystic Fibrosis - Discontinued Products
Cystic Fibrosis - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Cystic Fibrosis, H2 2016
Number of Products under Development for Cystic Fibrosis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd.1)
Number of Products under Development by Companies, H2 2016 (Contd.2)
Number of Products under Development by Companies, H2 2016 (Contd.3)
Number of Products under Development by Companies, H2 2016 (Contd.4)
Number of Products under Development by Companies, H2 2016 (Contd.5)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd.1)
Products under Development by Companies, H2 2016 (Contd.2)
Products under Development by Companies, H2 2016 (Contd.3)
Products under Development by Companies, H2 2016 (Contd.4)
Products under Development by Companies, H2 2016 (Contd.5)
Products under Development by Companies, H2 2016 (Contd.6)
Products under Development by Companies, H2 2016 (Contd.7)
Products under Investigation by Universities/Institutes, H2 2016
Cystic Fibrosis - Pipeline by Actelion Ltd, H2 2016
Cystic Fibrosis - Pipeline by Alaxia SAS, H2 2016
Cystic Fibrosis - Pipeline by AlgiPharma AS, H2 2016
Cystic Fibrosis - Pipeline by AmpliPhi Biosciences Corporation, H2 2016
Cystic Fibrosis - Pipeline by Arch Biopartners, Inc., H2 2016
Cystic Fibrosis - Pipeline by Arcturus Therapeutics, Inc., H2 2016
Cystic Fibrosis - Pipeline by Aridis Pharmaceuticals LLC, H2 2016
Cystic Fibrosis - Pipeline by AstraZeneca Plc, H2 2016
Cystic Fibrosis - Pipeline by Bayer AG, H2 2016
Cystic Fibrosis - Pipeline by BioAegis Therapeutics, Inc., H2 2016
Cystic Fibrosis - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Cystic Fibrosis - Pipeline by Calista Therapeutics, Inc., H2 2016
Cystic Fibrosis - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2016
Cystic Fibrosis - Pipeline by Celtaxsys, Inc., H2 2016
Cystic Fibrosis - Pipeline by Chrysalis Pharma SAS, H2 2016
Cystic Fibrosis - Pipeline by Cilian AG, H2 2016
Cystic Fibrosis - Pipeline by Concert Pharmaceuticals, Inc., H2 2016
Cystic Fibrosis - Pipeline by CRISPR Therapeutics, H2 2016
Cystic Fibrosis - Pipeline by CSA Biotechnologies LLC, H2 2016
Cystic Fibrosis - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2016
Cystic Fibrosis - Pipeline by DiscoveryBiomed, Inc., H2 2016
Cystic Fibrosis - Pipeline by Editas Medicine, Inc., H2 2016
Cystic Fibrosis - Pipeline by Eloxx Pharmaceuticals, Ltd., H2 2016
Cystic Fibrosis - Pipeline by Errant Gene Therapeutics, LLC, H2 2016
Cystic Fibrosis - Pipeline by Eumedica SA, H2 2016
Cystic Fibrosis - Pipeline by Galapagos NV, H2 2016
Cystic Fibrosis - Pipeline by Gilead Sciences, Inc., H2 2016
Cystic Fibrosis - Pipeline by GlaxoSmithKline Plc, H2 2016
Cystic Fibrosis - Pipeline by Grupo Praxis Pharmaceutical SA, H2 2016
Cystic Fibrosis - Pipeline by Horizon Pharma Plc, H2 2016
Cystic Fibrosis - Pipeline by ID Pharma Co., Ltd., H2 2016
Cystic Fibrosis - Pipeline by Immun System I.M.S. AB, H2 2016
Cystic Fibrosis - Pipeline by Insmed Incorporated, H2 2016
Cystic Fibrosis - Pipeline by Invion Limited, H2 2016
Cystic Fibrosis - Pipeline by JHL Biotech, Inc., H2 2016
Cystic Fibrosis - Pipeline by Kamada Ltd., H2 2016
Cystic Fibrosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
Cystic Fibrosis - Pipeline by La Jolla Pharmaceutical Company, H2 2016
Cystic Fibrosis - Pipeline by Lakewood-Amedex Inc, H2 2016
Cystic Fibrosis - Pipeline by Lamellar Biomedical Ltd, H2 2016
Cystic Fibrosis - Pipeline by Laurent Pharmaceuticals Inc., H2 2016
Cystic Fibrosis - Pipeline by Mast Therapeutics, Inc., H2 2016
Cystic Fibrosis - Pipeline by Merck & Co., Inc., H2 2016
Cystic Fibrosis - Pipeline by Microbion Corporation, H2 2016
Cystic Fibrosis - Pipeline by Mucokinetica Ltd., H2 2016
Cystic Fibrosis - Pipeline by Nivalis Therapeutics, Inc., H2 2016
Cystic Fibrosis - Pipeline by Novabiotics Limited, H2 2016
Cystic Fibrosis - Pipeline by Novartis AG, H2 2016
Cystic Fibrosis - Pipeline by OSE Immunotherapeutics, H2 2016
Cystic Fibrosis - Pipeline by Paranta Biosciences Limited, H2 2016
Cystic Fibrosis - Pipeline by Parion Sciences, Inc., H2 2016
Cystic Fibrosis - Pipeline by Pfizer Inc., H2 2016
Cystic Fibrosis - Pipeline by Pharmaxis Limited, H2 2016
Cystic Fibrosis - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2016
Cystic Fibrosis - Pipeline by Polyphor Ltd., H2 2016
Cystic Fibrosis - Pipeline by Progenra, Inc., H2 2016
Cystic Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2016
Cystic Fibrosis - Pipeline by ProQR Therapeutics N.V., H2 2016
Cystic Fibrosis - Pipeline by Protalix BioTherapeutics, Inc., H2 2016
Cystic Fibrosis - Pipeline by Proteostasis Therapeutics, Inc., H2 2016
Cystic Fibrosis - Pipeline by PTC Therapeutics, Inc., H2 2016
Cystic Fibrosis - Pipeline by Pulmatrix, Inc., H2 2016
Cystic Fibrosis - Pipeline by Raptor Pharmaceutical Corp., H2 2016
Cystic Fibrosis - Pipeline by ReveraGen BioPharma, Inc., H2 2016
Cystic Fibrosis - Pipeline by Savara Inc., H2 2016
Cystic Fibrosis - Pipeline by Shionogi & Co., Ltd., H2 2016
Cystic Fibrosis - Pipeline by Shire Plc, H2 2016
Cystic Fibrosis - Pipeline by Synovo GmbH, H2 2016
Cystic Fibrosis - Pipeline by TGV-Laboratories, H2 2016
Cystic Fibrosis - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016
Cystic Fibrosis - Pipeline by Verona Pharma Plc, H2 2016
Cystic Fibrosis - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2016
Cystic Fibrosis - Pipeline by Xenetic Biosciences (UK) Limited, H2 2016
Cystic Fibrosis - Pipeline by Zambon Company S.p.A., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Cystic Fibrosis - Dormant Projects, H2 2016
Cystic Fibrosis - Dormant Projects (Contd.1), H2 2016
Cystic Fibrosis - Dormant Projects (Contd.2), H2 2016
Cystic Fibrosis - Dormant Projects (Contd.3), H2 2016
Cystic Fibrosis - Dormant Projects (Contd.4), H2 2016
Cystic Fibrosis - Dormant Projects (Contd.5), H2 2016
Cystic Fibrosis - Dormant Projects (Contd.6), H2 2016
Cystic Fibrosis - Dormant Projects (Contd.7), H2 2016
Cystic Fibrosis - Dormant Projects (Contd.8), H2 2016
Cystic Fibrosis - Dormant Projects (Contd.9), H2 2016
Cystic Fibrosis - Dormant Projects (Contd.10), H2 2016
Cystic Fibrosis - Discontinued Products, H2 2016


LIST OF FIGURES

Number of Products under Development for Cystic Fibrosis, H2 2016
Number of Products under Development for Cystic Fibrosis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016

COMPANIES MENTIONED

Actelion Ltd
Alaxia SAS
AlgiPharma AS
AmpliPhi Biosciences Corporation
Arch Biopartners, Inc.
Arcturus Therapeutics, Inc.
Aridis Pharmaceuticals LLC
AstraZeneca Plc
Bayer AG
BioAegis Therapeutics, Inc.
Boehringer Ingelheim GmbH
Calista Therapeutics, Inc.
Catabasis Pharmaceuticals, Inc.
Celtaxsys, Inc.
Chrysalis Pharma SAS
Cilian AG
Concert Pharmaceuticals, Inc.
CRISPR Therapeutics
CSA Biotechnologies LLC
Cyclacel Pharmaceuticals, Inc.
DiscoveryBiomed, Inc.
Editas Medicine, Inc.
Eloxx Pharmaceuticals, Ltd.
Errant Gene Therapeutics, LLC
Eumedica SA
Galapagos NV
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Grupo Praxis Pharmaceutical SA
Horizon Pharma Plc
ID Pharma Co., Ltd.
Immun System I.M.S. AB
Insmed Incorporated
Invion Limited
JHL Biotech, Inc.
Kamada Ltd.
Kyorin Pharmaceutical Co., Ltd.
La Jolla Pharmaceutical Company
Lakewood-Amedex Inc
Lamellar Biomedical Ltd
Laurent Pharmaceuticals Inc.
Mast Therapeutics, Inc.
Merck & Co., Inc.
Microbion Corporation
Mucokinetica Ltd.
Nivalis Therapeutics, Inc.
Novabiotics Limited
Novartis AG
OSE Immunotherapeutics
Paranta Biosciences Limited
Parion Sciences, Inc.
Pfizer Inc.
Pharmaxis Limited
PhaseBio Pharmaceuticals, Inc.
Polyphor Ltd.
Progenra, Inc.
ProMetic Life Sciences Inc.
ProQR Therapeutics N.V.
Protalix BioTherapeutics, Inc.
Proteostasis Therapeutics, Inc.
PTC Therapeutics, Inc.
Pulmatrix, Inc.
Raptor Pharmaceutical Corp.
ReveraGen BioPharma, Inc.
Savara Inc.
Shionogi & Co., Ltd.
Shire Plc
Synovo GmbH
TGV-Laboratories
The International Biotechnology Center (IBC) Generium
Verona Pharma Plc
Vertex Pharmaceuticals Incorporated
Xenetic Biosciences (UK) Limited
Zambon Company S.p.A.
Skip to top


Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2016 US$ 2,000.00 Oct, 2016 · 260 pages

Ask Your Question

Cystic Fibrosis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: